Atlantic Equities announced it was Upgrade coverage of AbbVie Inc. in a research note on June 23, 2020. The analysts assigned an Overweight rating to the stock. Wolfe Research rated the stock as an Outperform in a research noted published on June 09, 2020. Argus rated the stock as a Buy in a research note published on June 02, 2020.
ALBAN CARLOS, the Vice Chairman of AbbVie Inc., sold 53325.0 shares at the valuation of $100.00 during an exchange that occurred on Jul 07, which implies that ALBAN CARLOS is holding 114,899 shares at the estimation of $5,332,555 dependent on the most recent closing price.
In another transaction, on May 12, SVP, US Commercial Operations of AbbVie Inc., Stewart Jeffrey Ryan, sold 23024.0 shares at the price of $90.00. After this activity, Stewart Jeffrey Ryan now keeps 52,760 shares of AbbVie Inc., esteemed at $2,072,211 with the most recent shutting price.
ABBV Recent Trade
The share price of ABBV descended by -$1.13 during the exchanging session on 07/31/20 to exchange at $94.91. AbbVie Inc. stock has an exchanging volume of 14.61 million shares, which is high, contrasted with its 3-months average volume of 9.33M shares. Its market capitalization has now reached to $169.25B and analysts have a consensus target price of $104.69 in the 12-month period.
ABBV Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, ABBV price has dropped by -2.27%. In the course of past three months sees the stock go up around 14.57%, while it has gain 17.14% over the past six months and 7.19% since the start of the year.
ABBV Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 8.62 billion, which was lesser than the gauge of 12.66B made by certain experts. For that equivalent quarter, AbbVie Inc. posted $2.34 earnings per share (EPS) which was above the consensus estimate of $2.19 by $0.15, which represents to an expansion by 6.80%.
ABBV Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on AbbVie Inc. has seen its stock exchanging -6.29% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +17.90% above its three-month low. A more extensive look sees ABBV exchanging -6.29% beneath its 52-week high and 51.73% above from its 52-week low price.
ABBV Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 1.81%, while it has a month to month instability of 2.02%. Ticker has an ATR (Average True Range) of 2.01 and a beta factor of 0.80.